Technical Analysis for BMRN - BioMarin Pharmaceutical Inc.

Grade Last Price % Change Price Change
grade F 86.0 2.74% 2.29
BMRN closed up 2.74 percent on Tuesday, April 23, 2019, on 1.25 times normal volume.

Earnings due: Apr 25

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BMRN trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Up 3 Days in a Row Strength 0.00%
Oversold Stochastic Weakness 0.00%
Slingshot Bearish Bearish Swing Setup 2.74%
Bullish Engulfing Bullish 2.74%
Calm After Storm Range Contraction 2.74%
Lower Bollinger Band Walk Weakness 2.74%
Lower Bollinger Band Touch Weakness 2.74%
Oversold Stochastic Weakness 2.74%

Older signals for BMRN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. The company's commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme used for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; and Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease. It also develops Vimizim, an enzyme replacement therapy that is in phase III clinical stage for the treatment of MPS IVA, a lysosomal storage disorder; PEG-PAL, an enzyme substitution therapy that is under Phase II clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trials for Pompe disease, a glycogen storage disorder; BMN-673, a clinical Phase I/II trial product for the treatment of cancer; and BMN-111, a peptide therapeutic that is under Phase I clinical trial for the treatment of achondroplasia. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation for the manufacture of Aldurazyme; and an agreement with Merck Serono S.A. for the further development and commercialization of BH4 in Kuvan for PKU and for other indications, and PEG-PAL. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Medicine Health Cancer California Treatment Of Cancer Drug Discovery Rare Diseases Virotherapy Serious Diseases Autoimmune Disease Inborn Errors Of Metabolism Biopharmaceuticals Enzyme Replacement Therapy Pompe Disease Pharmaceutical Wholesalers Phenylketonuria Biomarin Pharmaceutical Genetic Disease Iduronidase Intellectual Disability Lambert Eaton Myasthenic Lambert Eaton Myasthenic Syndrome Novato Pku
Is BMRN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 106.74
52 Week Low 79.13
Average Volume 1,037,697
200-Day Moving Average 95.4017
50-Day Moving Average 90.9446
20-Day Moving Average 89.166
10-Day Moving Average 87.7869
Average True Range 2.8557
ADX 21.94
+DI 18.4676
-DI 30.2233
Chandelier Exit (Long, 3 ATRs ) 85.4329
Chandelier Exit (Short, 3 ATRs ) 89.7871
Upper Bollinger Band 95.5245
Lower Bollinger Band 82.8075
Percent B (%b) 0.25
BandWidth 14.262163
MACD Line -1.7035
MACD Signal Line -1.0273
MACD Histogram -0.6762
Fundamentals Value
Market Cap 15.07 Billion
Num Shares 175 Million
EPS -1.07
Price-to-Earnings (P/E) Ratio -80.37
Price-to-Sales 12.04
Price-to-Book 5.17
PEG Ratio -4.46
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 91.42
Resistance 3 (R3) 91.21 89.20 90.51
Resistance 2 (R2) 89.20 87.82 89.30 90.21
Resistance 1 (R1) 87.60 86.97 88.40 87.81 89.91
Pivot Point 85.59 85.59 85.99 85.69 85.59
Support 1 (S1) 83.99 84.21 84.79 84.20 82.09
Support 2 (S2) 81.98 83.36 82.08 81.79
Support 3 (S3) 80.38 81.98 81.49
Support 4 (S4) 80.59